[{"id":"f7ccd756-4413-4530-bc65-1188b9dc3cbc","acronym":"DIAL","url":"https://clinicaltrials.gov/study/NCT03038672","created_at":"2021-01-18T14:57:44.271Z","updated_at":"2024-07-02T16:35:20.479Z","phase":"Phase 2","brief_title":"Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas","source_id_and_acronym":"NCT03038672 - DIAL","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" ALK • TMB • BCL2 • BCL6 • CD27 • IRF4","pipe":" | ","alterations":" BCL6 rearrangement • BCL2 rearrangement • CD27 expression","tags":["ALK • TMB • BCL2 • BCL6 • CD27 • IRF4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCL6 rearrangement • BCL2 rearrangement • CD27 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • varlilumab (CDX 1127) • ABP 206 (nivolumab biosimilar) • CMAB 819 (nivolumab biosimilar)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 52","initiation":"Initiation: 12/21/2018","start_date":" 12/21/2018","primary_txt":" Primary completion: 05/26/2023","primary_completion_date":" 05/26/2023","study_txt":" Completion: 10/25/2024","study_completion_date":" 10/25/2024","last_update_posted":"2024-02-07"},{"id":"dbd8060f-f9fc-4e93-8baf-7895d90d342a","acronym":"Mel-65","url":"https://clinicaltrials.gov/study/NCT03617328","created_at":"2021-01-29T07:17:48.889Z","updated_at":"2024-07-02T16:35:20.701Z","phase":"Phase 1/2","brief_title":"Vaccination With 6MHP, With or Without Systemic CDX-1127, in Patients With Stage II-IV Melanoma","source_id_and_acronym":"NCT03617328 - Mel-65","lead_sponsor":"Craig L Slingluff, Jr","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e varlilumab (CDX 1127) • Hiltonol (poly-ICLC)"],"overall_status":"Completed","enrollment":" Enrollment 33","initiation":"Initiation: 11/13/2018","start_date":" 11/13/2018","primary_txt":" Primary completion: 01/19/2024","primary_completion_date":" 01/19/2024","study_txt":" Completion: 01/19/2024","study_completion_date":" 01/19/2024","last_update_posted":"2024-02-06"},{"id":"463880b8-db67-43d7-bf2e-e66e4dd193ce","acronym":"RiVa","url":"https://clinicaltrials.gov/study/NCT03307746","created_at":"2021-01-18T16:20:12.078Z","updated_at":"2024-07-02T16:35:33.664Z","phase":"Phase 2a","brief_title":"A Combination of Rituximab and Varlilumab Immunotherapy in Patients With B-cell Lymphoma","source_id_and_acronym":"NCT03307746 - RiVa","lead_sponsor":"University Hospital Southampton NHS Foundation Trust","biomarkers":" CD20","pipe":" | ","alterations":" CD20 expression","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • varlilumab (CDX 1127)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 26","initiation":"Initiation: 11/23/2017","start_date":" 11/23/2017","primary_txt":" Primary completion: 02/18/2021","primary_completion_date":" 02/18/2021","study_txt":" Completion: 03/31/2024","study_completion_date":" 03/31/2024","last_update_posted":"2023-10-12"},{"id":"976ac03b-ec3e-471c-b247-2d7d7e9d91d8","acronym":"","url":"https://clinicaltrials.gov/study/NCT04081688","created_at":"2021-01-18T19:59:05.021Z","updated_at":"2024-07-02T16:35:42.115Z","phase":"Phase 1","brief_title":"Atezolizumab and Varlilumab in Combination With Radiation Therapy for NSCLC","source_id_and_acronym":"NCT04081688","lead_sponsor":"Rutgers, The State University of New Jersey","biomarkers":" BRAF • ALK • ROS1 • LAG3 • IDO1 • CD27","pipe":" | ","alterations":" BRAF V600E • EGFR mutation • BRAF V600 • EGFR T790M • ALK rearrangement • ROS1 rearrangement","tags":["BRAF • ALK • ROS1 • LAG3 • IDO1 • CD27"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • EGFR mutation • BRAF V600 • EGFR T790M • ALK rearrangement • ROS1 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • varlilumab (CDX 1127)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 16","initiation":"Initiation: 09/11/2019","start_date":" 09/11/2019","primary_txt":" Primary completion: 04/27/2022","primary_completion_date":" 04/27/2022","study_txt":" Completion: 04/30/2024","study_completion_date":" 04/30/2024","last_update_posted":"2023-07-25"},{"id":"1a5afad7-27ed-4e1a-9e4f-e5b3eebab5a7","acronym":"DERIVe","url":"https://clinicaltrials.gov/study/NCT03688178","created_at":"2021-01-18T18:04:45.994Z","updated_at":"2024-07-02T16:35:42.645Z","phase":"Phase 2","brief_title":"DC Migration Study to Evaluate TReg Depletion In GBM Patients With and Without Varlilumab","source_id_and_acronym":"NCT03688178 - DERIVe","lead_sponsor":"Annick Desjardins, MD","biomarkers":" MGMT • IL2RA • CD4 • FOXP3 • CCL3 • ISG20","pipe":"","alterations":" ","tags":["MGMT • IL2RA • CD4 • FOXP3 • CCL3 • ISG20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temozolomide • varlilumab (CDX 1127)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 43","initiation":"Initiation: 08/26/2020","start_date":" 08/26/2020","primary_txt":" Primary completion: 03/01/2025","primary_completion_date":" 03/01/2025","study_txt":" Completion: 03/01/2025","study_completion_date":" 03/01/2025","last_update_posted":"2023-07-19"},{"id":"6a6d4216-6cf7-4fe5-a984-fa47ca82976d","acronym":"","url":"https://clinicaltrials.gov/study/NCT01460134","created_at":"2021-01-18T06:04:13.189Z","updated_at":"2024-07-02T16:37:14.288Z","phase":"Phase 1","brief_title":"A Study of CDX-1127 (Varlilumab) in Patients With Select Solid Tumor Types or Hematologic Cancers","source_id_and_acronym":"NCT01460134","lead_sponsor":"Celldex Therapeutics","biomarkers":" BRAF • CD27","pipe":" | ","alterations":" BRAF V600E • BRAF V600 • CD27 expression","tags":["BRAF • CD27"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • BRAF V600 • CD27 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e varlilumab (CDX 1127)"],"overall_status":"Completed","enrollment":" Enrollment 90","initiation":"Initiation: 10/01/2011","start_date":" 10/01/2011","primary_txt":" Primary completion: 12/01/2015","primary_completion_date":" 12/01/2015","study_txt":" Completion: 10/16/2017","study_completion_date":" 10/16/2017","last_update_posted":"2018-01-31"}]